Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Rong Xu, Difei Lian, Yan Xie, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 7, pp. 134-134
Open Access | Times Cited: 10

Showing 10 citing articles:

Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects
Søren Møller, Nina Kimer, Jens D. Hove, et al.
European Journal of Preventive Cardiology (2025)
Closed Access | Times Cited: 2
Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, et al.
Diabetes & Metabolism (2023) Vol. 50, Iss. 1, pp. 101506-101506
Open Access | Times Cited: 35
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
Eleni Michalopoulou, J Thymis, Stamatios Lampsas, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 428-428
Open Access | Times Cited: 1
Post‐hoc analysis of the tofogliflozin post‐marketing surveillance study (J‐STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI
Hiroyuki Uchinuma, Mitsunori Matsushita, Masaya Tanahashi, et al.
Journal of Diabetes Investigation (2025)
Open Access
Sodium-Glucose Transport Protein-2 Inhibitors in the Treatment of Non-alcoholic Steatohepatitis: An Evidence-Based Review
Xueyan Lv, Dianchao Mi Mi, Xin Yan, et al.
Hepatitis Monthly (2025) Vol. 25, Iss. 1
Open Access
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Exploring Systemic Impacts and Innovative Therapies
Parag Jain, Akanksha Jain, Rohitas Deshmukh, et al.
Clinics and Research in Hepatology and Gastroenterology (2025), pp. 102584-102584
Closed Access
Mice hepatic organoids for modeling nonalcoholic fatty liver disease and drug response
Zheng Zhou, Xiyan Zheng, Maoyun Xie, et al.
Stem Cells and Development (2024) Vol. 33, Iss. 15-16, pp. 387-398
Closed Access | Times Cited: 1
Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection
Shibing Tao, S. Guo, Nanwei Tong
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 8, pp. 642-657
Closed Access
Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs
Divya Rajagopal, Sulthan Al Rashid
Journal of Diabetology (2024) Vol. 15, Iss. 4, pp. 458-459
Open Access
A Systematic Review and Meta-Analysis of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors and Their Impact on the Management of Heart Failure
Nestor Lemos Ferreira, Abiodun Bamidele Adelowo, Zahid Khan
Cureus (2024)
Open Access
Page 1

Scroll to top